Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06056804 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint revisedv3 Show 8 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Jul 1, 2024 to Dec 1, 2024
    • Start date changed from estimate of Dec 1, 2023 to Jan 3, 2024
    • Eligibility criteria shortened, about 137 words
    • Secondary endpoints: 11 to 7
    • Study description shortened, about 7 words
    • Site contacts updated at 2 of 2 sites
    • Publications: 4 to 5
  2. Start date: Oct 9, 2023 to Dec 1, 2023
    • Secondary endpoints: details revised at 3 of 11 entries
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open, prospective, multi-center, single-arm phase II clinical study assessing the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1 inhibitor and thymalfasin in patients with pMMR/MSS locally advanced middle and low rectal cancer.
Trial Details
NCT Number NCT06056804
Lead Sponsor Beijing Friendship Hospital
Collaborators: Peking Union Medical College Hospital
Conditions
(from sponsor)		 Locally Advanced Rectal Cancer
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov